Registry of Endovascular Closure of Patent Foramen Ovale in Russia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study involves patients over 18 years old who have undergone endovascular closure of a patent foramen ovale (PFO) across 29 medical centers in the Russian Federation. It aims to gather data on the relationship between PFO and cryptogenic strokes, which are strokes of undetermined origin. Participants will provide informed consent and personal data as part of their inpatient medical care. The study seeks to enhance understanding of PFO's role in ischemic events and improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with an ischemic event (cryptogenic ischemic stroke, transient ischemic attack, embolism of other organs and systems) associated with a PFO;
2. Presence of an open oval confirmed by ultrasound diagnostic methods;
3. Age of patients from 18 years;
4. Life expectancy of at least 1 year;
5. Signed informed consent for endovascular closure of a PFO.

Exclusion Criteria:

1. Inability to receive antiplatelet therapy;
2. Presence of acute inflammatory diseases;
3. Acute stage of cerebral circulatory failure (30 days);
4. Myocardial infarction or aortocoronary bypass surgery within the previous 30 days;
5. Carotid or vertebral artery dissection;
6. Severe cardiac valve pathology;
7. Presence of blood clots in the cardiac cavities;
8. Refusal of the patient to participate in the study.

Where it's running

• National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
  Moscow, Russia Recruiting

Study contacts

• Study coordinator: Andrey Tereschenko
• Email: andrew034@yandex.ru
• Phone: 84954150144

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term outcomes after PFO closure at Severance Hospital

  This registry tests how well percutaneous PFO closure works over the long term and what factors predict residual shunt, new atrial fibrillation, or other outcomes in adults who had the procedure.

  Recruiting Yonsei University · Seoul · NCT07724171

• P3 Occluder System for closing a heart opening (PFO) after stroke

  We are testing the P3 Occluder System to see if it safely and effectively closes a patent foramen ovale in adults who had a stroke related to their heart opening.

  Recruiting Recross Cardio, Inc. · Belgrade · NCT07698951

• PFO-Directed Therapy for Migraines: Closing the Hole or Using a Blood Thinner

  This study tests whether closing a patent foramen ovale (PFO) plus 24 weeks of prasugrel works better for long-term migraine relief than prasugrel alone in people whose migraines improve on blood-thinning therapy.

  Recruiting Phase 3 Columbia University · New York, New York · NCT07629635

• Comparing Cocoon vs Amplatzer PFO Occluders in Adults After Stroke or TIA

  This trial tests whether the Cocoon PFO Occluder works as well as the Amplatzer PFO Occluder in adults who had a cryptogenic stroke or TIA and have a PFO requiring closure.

  Recruiting Sahajanand Medical Technologies Limited · Bad Oeynhausen, North Rhine-Westphalia (Nordrhein-Westfalen) · NCT07380490

• Percutaneous repair of the atrial septum using the P3 Occluder System for PFO closure

  This trial tests the P3 Occluder System to close a patent foramen ovale (PFO) in adults 18–65 who have had a stroke that may be linked to their PFO.

  Recruiting at 5 sites Recross Cardio, Inc. · Los Angeles, California and 4 other locations · NCT07172464

• Closing a PFO to improve glymphatic function and migraine symptoms

  This study will see if closing a patent foramen ovale (PFO) improves glymphatic system function and reduces migraine attacks in adults with PFO and migraine.

  Recruiting at 2 sites First Affiliated Hospital Xi'an Jiaotong University · Luoyang, Henan and 1 other locations · NCT07170176

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.